METABIOMED plans share buyback of 277,777 shares worth ₩1.0bn
METABIOMED.CO.,LTD filed a share buyback plan on Nov 17, 2026 to acquire 277,777 shares for a planned amount of ₩1.0bn. The buyback is to be made through direct on-market acquisition on KOSDAQ, from Nov 18, 2026 to Dec 31, 2026.
Key facts
| Planned shares | 277,777 shares |
|---|---|
| Planned amount | ₩1.0bn |
| Period start | Nov 18, 2026 |
| Period end | Dec 31, 2026 |
| Acquisition method | direct on-market acquisition through KOSDAQ market |
Comparison
| Amount as % of prior-year revenue (calculated) | 1.0% |
|---|---|
| Revenue 2025 | ₩103.0bn |
| Revenue 2024 | ₩94.0bn |
| Revenue 2023 | ₩83.1bn |
Context
By our calculation, the planned ₩1.0bn amount is 1.0% of FY2025 revenue of ₩103.0bn. The company is a manufacturer of medical supplies and related other medicaments.
Key metrics
Share buybacks
| Buyback decided, last 3 months | ₩1.0bn |
|---|---|
| Buyback decided, last 3 months, % of shares | 1.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩4.0bn |
| Buyback decided, last 12 months, % of shares | 3.8% |
| Shares acquired, last 12 months | ₩3.0bn |
| Shares acquired, last 12 months, % of shares | 2.8% |
| Treasury shares cancelled, last 12 months | ₩2.7bn |
| Treasury shares cancelled (number), last 12 months | 922,856 shares |
| Treasury shares cancelled, last 12 months, % of shares | 3.4% |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗